On its thirteenth anniversary, MEDSIR Celebrates a successful history that is redefining independent cancer research worldwide. Founded in Barcelona in 2012 by oncologists specializing in breast cancer Javier Cortes y Antonio Llombart, together with Maria Campos, current CEO, the organization combines scientific excellence, international collaboration, and unique operational agility to bring innovative solutions to medical professionals and cancer patients.
With strategic headquarters in Barcelona y Boston, and growing activity in Europe, America and Asia, MEDSIR has proven to be a key player in the development and efficient management of innovative ideas in oncology, always meeting the highest quality standards.
A Measurable Impact in Figures
The numbers speak for themselves: in these 13 years, MEDSIR has collaborated with more than 600 researchers from around the world, supporting the generation of new research concepts. This synergy has culminated in the development and execution of 65 clinical trials, carried out in more than 200 medical centers spread over 14 countries. More importantly, more than 2.600 patients Globally, they have participated in these studies, directly benefiting from the research promoted by the organization.
"At MEDSIR we don't just support research: we create the conditions for independent and courageous science to thrive," he says. Giulia Raimondi, Strategic Research Development Chief at MEDSIR. “From the beginning, our mission has been to accelerate the path from concept to clinical trial, relying on a robust network of over 600 talented researchers focused on the real needs of patients. Seeing more than 2.600 patients from around the world participating in our studies is the most powerful validation of that mission.”
Scientific Excellence and Global Expansion
MEDSIR's commitment to scientific excellence is undeniable. The company has generated 146 scientific contributionsIncluding 52 publications in peer-reviewed journals and 94 presentations at prestigious international conferences. It is worth noting that a 67 of your publications have appeared in Q1 journals, the highest impact quartile, such as The Lancet, Nature or Journal of Clinical Oncology, reflecting the high relevance of his work.
“Our strength lies in our ability to connect brilliant ideas, clinical needs, and efficient trial execution,” Raimondi adds. “By supporting researchers with an agile structure and global reach, we help turn promising concepts into robust data and viable treatments more quickly.”
International expansion has been key. From its headquarters in Barcelona, MEDSIR established a second office in Boston to strengthen its presence in the United States. In 2022, it took a significant step by forming a strategic alliance in Brazil with Oncoclinics & Co, the largest oncology group in Latin America, with the goal of scaling independent clinical research across several continents. Its hybrid approach, which combines the rigor of investigator-led studies with the standards of trials promoted by the pharmaceutical industry, offers a unique avenue for innovation.
Looking To The Future
“MEDSIR is not just a catalyst for science; it’s a platform where the best minds and companies in oncology come together to rethink what’s possible,” concludes Giulia Raimondi. “As we celebrate these 13 years, we are more committed than ever to pushing the boundaries of cancer research.”
Looking to the future, MEDSIR plans to continue expanding its global presence, investing in disruptive solutions such as Artificial Intelligence and precision oncology, and continue promoting research that addresses unmet medical needs. The organization continues to connect key international players, including major pharmaceutical and biotech companies, under the fundamental belief that innovation in cancer research should have no borders.
Any questions about this news?
Talk to Coexia, the AI of the foreign trade
